Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: AbCellera Biologics Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001703057-26-000046
| Line item | Six months ended June 30, 2025 | Six months ended June 30, 2026 |
|---|---|---|
| Other assets | 13,450 | 1,838 |
| Net cash used in operating activities | (43,958) | (7,600) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (24,001) | (5,963) |
| Purchase of marketable securities | (291,542) | (308,184) |
| Proceeds from marketable securities | 303,437 | 293,557 |
| Receipt of grant funding | 6,448 | 6,955 |
| Long-term investments and other assets | (18,218) | (105) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is AbCellera Biologics Inc.'s capex?
- AbCellera Biologics Inc. (ABCL) reported capex of $2.13M in Q2 2026.
- How has AbCellera Biologics Inc.'s capex changed year-over-year?
- AbCellera Biologics Inc.'s capex decreased by 84.0% year-over-year, from $13.37M to $2.13M.
- What is the long-term trend for AbCellera Biologics Inc.'s capex?
- Over 4 years (2021 to 2025), AbCellera Biologics Inc.'s capex has grown at a -7.5% compound annual growth rate (CAGR), from $58.45M to $42.77M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about AbCellera Biologics Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude